|
1
|
ten Bokkel Huinink W, Gore M, Carmichael
J, Gordon A, Malfetano J, Hudson I, Broom C, Scarabelli C, Davidson
N, Spanczynski M, Bolis G, Maimstrom H, Coleman R, Fields C and
Heron F: Topotecan versus paclitaxel for the treatment of recurrent
epithelial ovarian cancer. J Clin Oncol. 15:2183–2193.
1997.PubMed/NCBI
|
|
2
|
Schiller JH, Adak S, Cella D, DeVore RF
III and Johnson DH: Topotecan versus observation after cisplatin
plus etoposide in extensive-stage small-cell lung cancer: E7593-a
phase III trial of the Eastern Cooperative Oncology Group. J Clin
Oncol. 19:2114–2122. 2001.
|
|
3
|
von Pawel J, Schiller JH, Shepherd FA,
Fields SZ, Kleisbauer JP, Chrysson NG, Stewart DJ, Clark PI, Palmer
MC, Depierre A, Carmichael J, Krebs JB, Ross G, Lane SR and Gralla
R: Topotecan versus cyclophosphamide, doxorubicin, and vincristine
for the treatment of recurrent small-cell lung cancer. J Clin
Oncol. 17:658–667. 1999.PubMed/NCBI
|
|
4
|
Pizzolato JF and Saltz LB: The
camptothecins. Lancet. 361:2235–2242. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Saltz LB, Cox JV, Blanke C, Rosen LS,
Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta
N, Elfring GL and Miller LL: Irinotecan plus fluorouracil and
leucovorin for metastatic colorectal cancer. N Engl J Med.
343:905–914. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Douillard JY, Cunningham D, Roth AD,
Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J,
Alakl M, Gruia G, Awad L and Rougier P: Irinotecan combined with
fluorouracil compared with fluorouracil alone as first-line
treatment for metastatic colorectal cancer: a multicenter
randomized trial. Lancet. 355:1041–1047. 2000. View Article : Google Scholar
|
|
7
|
Cao Z, Harris N, Kozielski A, Vardeman D,
Stehlin J and Giovanella B: Alkyl esters of camptothecin and
9-nitrocamptothecin: Synthesis, in vitro pharmacokinetics,
toxicity, and antitumor activity. J Med Chem. 41:31–37. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cao ZS, Mendoza J, Dejesus A and
Giovanella B: Synthesis and anti-tumor activity of alkenyl
camptothecin esters. Acta Pharmacol Sin. 26:235–241. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cao Z, Mendoza J, Dejesus A, Vardeman D
and Giovanella B: Synthesis and antitumor activity of aromatic
camptothecin esters. Int J Mol Med. 21:477–487. 2008.PubMed/NCBI
|
|
10
|
Cao Z, Mendoza J, Kozielski A, Liu X,
Dejesus A, Wang Y, Zhan CG, Vardeman D and Giovanella B: Anticancer
activity of new haloalkyl camptothecin esters against human cancer
cell lines and human tumor xenografts grown in nude mice.
Anticancer Agents Med Chem. 12:818–828. 2012. View Article : Google Scholar
|
|
11
|
Cao Z, Kozielski A, Harris N, Vardeman D
and Giovanella D: Sulfuric acid catalyzed preparation of alkyl and
alkenl camptothecin ester derivatives and antitumor activity
against human xenografts grown in nude mice. Open J Med Chem.
2:10–14. 2012. View Article : Google Scholar
|
|
12
|
Cao Z, Kozielski A, Liu X, Wang Y,
Vardeman D and Giovanella B: Crystalline
camptothecin-20(S)-O-propionate hydrate: a novel anticancer agent
with strong activity against 19 human tumor xenografts. Cancer Res.
69:4742–4749. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cao ZS, Pantazis P, Mendoza J, Early J,
Kozielski A, Harris N and Giovanella B: Structure-activity
relationship of alkyl 9-nitrocamptothecin esters. Acta Pharmacol
Sin. 24:109–119. 2003.PubMed/NCBI
|
|
14
|
Cao Z, Pantazis P, Mendoza J, Early J,
Kozieslki A, Harris N, Vardeman D, Liehr J, Stehlin J and
Giovanella B: Structure-activity relationship of alkyl camptothecin
esters. Annu N Y Acad Sci. 992:122–135. 2000.
|
|
15
|
Liu X, Wang Y, Vardeman D, Cao Z and
Giovanella B: Development and validation of a reverse-phase HPLC
with fluorescence detector method for simultaneous determination of
CZ48 and its active metabolite camptothecin in mouse plasma. J
Chromatogr B Analyt Technol Biomed Life Sci. 867:84–89. 2008.
View Article : Google Scholar
|
